| |
Immune checkpoint inhibitors offer significant survival benefit, yet many patients do not respond to these treatments. Dosing optimization offers hope. Learn how to maximize therapeutic efficacy and minimize toxicity of ICIs in our guide. .png)
|
|
Today’s Big NewsOct 4, 2024 |
|
These awards honor CROs that excel in innovation, quality, and leadership, highlighting their crucial role in advancing life sciences and improving patient outcomes. Enter now! 
|
|
| By James Waldron Johnson & Johnson’s deprioritization of its infectious disease pipeline has claimed another victim in the form of its dengue virus vaccine mosnodenvir. |
|
|
|
By Gabrielle Masson Precision medicines biotech Relay Therapeutics is shedding about 10% of its workforce in efforts to streamline the organization. |
By Nick Paul Taylor A minority of patients taking Ultragenyx Pharmaceutical’s Wilson disease gene therapy UX701 have come off standard-of-care drugs, leading the biotech to enroll a new cohort on a tweaked regimen designed to dial up the efficacy. |
By James Waldron Against the backdrop of a Cas9 patent battle that refuses to die, Editas Medicine is cashing in a chunk of the licensing rights from Vertex Pharmaceuticals to the tune of $57 million. |
|
This white paper delves into key challenges in ADC development and explores new drug product capabilities in cytotoxic drug development and manufacturing, accelerating timelines to IND filing and beyond. 
|
|
By Darren Incorvaia,Zoey Becker Prothena, a company focused on neurodegenerative diseases, is shaking up its C-suite. The exec moves were announced just a day after the science underlying Prothena’s Parkinson’s drug prasinezumab was implicated in a massive research misconduct scandal but are unrelated, a company spokesperson told Fierce in an email. |
By Darren Incorvaia Gene therapy icon Jim Wilson, M.D., Ph.D., made waves in August when he announced that he was leaving the University of Pennsylvania after more than 30 years to create—and lead—two new biotech companies. One of those companies, a contract research organization focused on genetic medicines called Franklin Biolabs, officially launched this week. |
By Ayla Ellison,Fraiser Kansteiner This week on "The Top Line," Fierce Pharma’s Fraiser Kansteiner and Arnold & Porter’s Dan Kracov break down the BIOSECURE Act's potential impact on the life sciences industry and what comes next after the House of Representatives' recent vote. |
By Fraiser Kansteiner Recordati is floating $825 million upfront—plus another $250 million in potential commercial milestones—to get its hands on the global rights to Sanofi’s rare disease biologic Enjaymo. In 2022, Enjaymo became the first and only therapy specifically approved by the FDA for treating patients with the uncommon blood disorder cold agglutinin disease. |
By Emma Beavins Four leading cancer centers are leveraging their data resources and AI to gain ground on cancer. |
By Eric Sagonowsky On the same day as Roche's Pharma Day in London, the drugs giant struck a high-dollar deal with Chinese-American biotech Regor for the latter's CDK inhibitors. Legend's momentum continued with a strong survival showing for Johnson & Johnson-partnered Carvykti and the announcement of a planned R&D facility in the U.S. WuXi AppTec and WuXi Biologics are considering hiving off certain assets amid biosecurity scrutiny. Plus more. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce Pharma’s Fraiser Kansteiner and Arnold & Porter’s Dan Kracov break down the BIOSECURE Act's potential impact on the life sciences industry and what comes next after the House of Representatives' recent vote. |
|
|---|
|
|
|
Optimize Bioprocessing with Scalable Solutions – Achieve Higher Yields, Greater Purity, and Faster Time-to-market. 
|
|
Whitepaper Unlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
Whitepaper Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
Whitepaper Unique Solutions for Drug Discovery and Development Sponsored by: Cell Signaling Technology |
Whitepaper When the fate of your company hangs in the balance, you need expert guidance to navigate the complexities of biotechnology development and to make informed decisions. Sponsored by: WCG |
Whitepaper Power non-invasive, self-sampling solutions using the Colli-Pee™️ first-void urine collection device. Learn more. Sponsored by: DNA Genotek |
Whitepaper Facing roadblocks in drug development? Uncover how phase-appropriate technology transfers can help you navigate challenges and speed up your journey to market. Sponsored by: Veranova |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
